Navigation Links
Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain
Date:1/19/2009

BASEL, Switzerland, January 19 /PRNewswire-FirstCall/ --

- Tamiflu Remains Fully Effective Against 94 Percent of Circulating Influenza Viruses in Europe

Latest surveillance data coming through the European Centre for Disease Prevention and Control (ECDC) from virologists and clinicians indicates that the influenza A(H3N2) virus is the predominant strain in Europe so far this season. Based on the data published by ECDC Roche confirms that the oral antiviral Tamiflu (oseltamivir) is fully active against influenza A(H3N2) and influenza B, which currently comprise 94 percent of circulating viruses in Europe this year.(1)

Tamiflu resistance reported in the 2008-2009 influenza seasons is confined to H1N1. No resistance has been seen with other circulating seasonal viruses - H3N2 and influenza B.

"Recent media reporting has elevated awareness of the H1N1 seasonal resistance seen this year in the United States and the Far East. However, in Europe the picture is different with H3N2 being the dominant strain so far. The circulating H3N2 viruses, which often cause a more severe illness than H1N1, are sensitive to oseltamivir, which means that oseltamivir will be active against the vast majority of influenza infections in Europe this season, if current trends continue," comments Prof Albert Osterhaus, Head of Virology, Erasmus Medical Centre, Rotterdam. "It is important that doctors understand that oseltamivir remains an effective treatment for patients across Europe."

Vaccines are considered first line in the management of seasonal influenza, however, people who show symptoms or have been in close contact with an infected person may require more immediate intervention, such as Tamiflu, which can rapidly treat and prevent influenza.

European surveillance data

The ECDC reports that in the 2008-2009 season, influenza activity is increasing rapidly acr
'/>"/>

SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
2. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
3. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
4. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
5. Rising H9N2 Influenza Replikin Count Has Doubled That of H5N1
6. DaVita Launches Flu Fighter Program in Support of National Influenza Week
7. Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
8. A New Way to Predict Outbreaks: Replikin Peptide Concentration in H5N1 Influenza Virus Genome as a Marker for Lethal Outbreaks
9. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
10. Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
11. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Follow us on ... each type of cholesterol carrier or lipoprotein in the ... excessive cholesterol levels in the body, especially along the ... heart attack and other cardiovascular disorders. Cardiovascular Diseases (CVD) ... for cholesterol levels on a regular basis, to assess ...
(Date:9/30/2014)... , September 30, 2014 ... browsing of chemistry in documents ... solutions and consulting services for life science research, ... and generate Markush structures from documents. ... intellectual property, however generating and understanding Markush structures ...
(Date:9/30/2014)...  KemPharm, Inc., a clinical-stage specialty pharmaceutical company ... new molecular entity (NME) prodrugs, announced today that ... issued U.S. Patent No. 8,816,083 to KemPharm for ... Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydromorphone, ... The patent, which extends through 2032, provides ...
(Date:9/30/2014)... iLab Solutions announced the results of its ... focuses on core facility operations, growth and utilization as ... , In its 4th year running, a number of ... year-over-year decrease in the percentage of revenue that comes ... the constraints of this trend. When asked, “What are ...
Breaking Biology Technology:Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3
... , By Laura Gaidar, Kristin ... Loraine Upham , PerkinElmer ... Introduction , AlphaScreen ... assay development and high throughput screening applications. PerkinElmer Life Sciences has developed ...
... , Introduction ... within the brain can lead to several disease states, including ... to discover the mode of action of various transmitters, in ... binding of the neurotransmitter to its receptor alters the production ...
... , ... radiometric screening assays. The Wallac MicroBeta effectively measures both plate types. , ... one above the sample and one below. , ... are conducted with the upper PM tube only. A comparison is made ...
Cached Biology Technology:Comparison of Performance between the AlphaQuest - HTS and the Fusion α Multilabel Reader for Detection of cAMP 2Comparison of Performance between the AlphaQuest - HTS and the Fusion α Multilabel Reader for Detection of cAMP 3Comparison of Performance between the AlphaQuest - HTS and the Fusion α Multilabel Reader for Detection of cAMP 4In Vitro Measurement of the Second Messenger cAMP: RIA vs. FlashPlate 2In Vitro Measurement of the Second Messenger cAMP: RIA vs. FlashPlate 3In Vitro Measurement of the Second Messenger cAMP: RIA vs. FlashPlate 4Counting FlashPlates on the Wallac MicroBeta 2Counting FlashPlates on the Wallac MicroBeta 3
(Date:9/30/2014)... of perilous threats in today,s ocean. From overfishing ... fragile coral ecosystems are disappearing at unprecedented rates ... of corals surrounding the island of Moorea in ... tropical environment: coral guard-crabs. New research from the ... scientist Seabird McKeon and the museum,s predoctoral fellow ...
(Date:9/30/2014)... Winners of The Economist,s prestigious Innovation awards 2014 will ... at the JW Marriott Hong Kong on Friday, October 10 th ... experiences and the lessons those hold for others. The awards, which ... past decade, will be presented at a ceremony in ... be the first time the ceremony has come to ...
(Date:9/29/2014)... to tar tended to be lower for smokers of ... to nicotine tended to be lower. , Slim cigarettes ... countries around the world. Previous studies have shown that ... of these cigarettes are lower than those in regular ... smoke are not necessarily linked to a reduced exposure ...
Breaking Biology News(10 mins):Smithsonian scientists discover coral's best defender against an army of sea stars 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Slim cigarette smokers not exposed to more harmful chemicals 2
... and Director of Research at the Molecular ... release of a new approach to simulation of ... Nature,Biotechnology.,The research article, entitled "Automatic generation of ... MSI's discrete stochastic event simulator, which keeps track,of ...
... are failing to stem the rising rate of HIV infection, ... BMJ. , An estimated 38 million people worldwide, including over ... record 4.8 million became infected in 2003. , The underlying ... also represents a failure of prevention, write the authors. , ...
... the central nervous system (CNS), where it influences neurotransmission ... to study brain function gene by gene. Symposium proceedings ... Experimental Research address the effects of alcohol on what ... animal models. , "All of our cells have exactly ...
Cached Biology News:MSI releases 'moleculizer' - a new approach to simulation of intracellular biochemical networks 2MSI releases 'moleculizer' - a new approach to simulation of intracellular biochemical networks 3Alcohol's effects on gene expression in the central nervous system 2Alcohol's effects on gene expression in the central nervous system 3Alcohol's effects on gene expression in the central nervous system 4